GET DAILY SIGNALSWhy Is Alignment Healthcare (ALHC) Stock Down -8.31% Today?
Key Takeaways
- ALHC shares fell 8.31% intraday, trading near $7.39 versus a prior close of $8.06.
- The selloff follows the company's third-quarter report, which featured a surge in medical costs and a steep cut to full-year adjusted EBITDA guidance.
- Secondary pressure came from a KeyBanc downgrade to Sector Weight from Overweight and a weaker-than-expected Star Rating on its largest California contract.
- Revenue and membership growth remained strong, but investors focused on deteriorating profitability and margin visibility.
- Traders are watching the upcoming Annual Enrollment Period results and 2027 membership and margin trajectory.
- For more detail, explore Price Targets, Earnings, and Forecast pages for ALHC.
- Discover Trending AI Robots to see which automated strategies are performing in today's market.
Opening Summary
Alignment Healthcare, Inc. (ALHC), a technology-enabled Medicare Advantage insurer focused on senior healthcare, saw its stock plunge more than 8% in Thursday's session. The shares traded near $7.39, down from a prior closing price of $8.06, extending losses that followed Wednesday's after-hours earnings release. The immediate trigger was a third-quarter report that beat on revenue but exposed a sharp rise in medical costs, prompting management to slash full-year profitability guidance.
Earnings Results and Guidance Cut
The primary catalyst behind the decline was the company's Q3 2026 report. Revenue grew roughly 37% year over year to about $1.36 billion, beating consensus estimates, and health plan membership climbed 31% to 301,200. However, the adjusted medical benefits ratio (MBR) rose to 89.5%, up about 240 basis points from a year earlier, reflecting higher provider appeals and disputes tied to a claims-system migration, along with elevated costs in skilled-nursing and catastrophic cases.
The profit reset proved more consequential than the top-line beat. Management cut full-year adjusted EBITDA guidance to at least $100 million, down sharply from a prior range of $145 million to $163 million, and reduced adjusted gross profit guidance to at least $575 million from $630 million to $650 million. Fourth-quarter guidance implied a further step-up in medical costs, signaling that the elevated claims environment is expected to persist into the year's end.
Analyst Downgrade
Compounding the selling pressure, KeyBanc downgraded ALHC to Sector Weight from Overweight. The firm cited reduced confidence in the company's 2027 EBITDA baseline given higher costs that developed during the third quarter, as well as limited visibility into the company's Star Ratings for the 2029 payment year.
Star Ratings Setback
Investors also weighed a structural concern: the company's largest contract, its California HMO plan, dropped to a 3.5 Star Rating for payment year 2028. Although six of seven eligible plans maintained four-star or better ratings, the California downgrade represents a meaningful revenue headwind tied to Alignment's most concentrated exposure. Management indicated it is pursuing Stars litigation and risk-adjustment improvements as partial offsets.
Market Context and Trading Activity
Trading volume was notably elevated as investors repriced the stock in the wake of the earnings reset, with Wednesday's session already showing a sharp spike in turnover versus the stock's recent average. The move was largely company-specific rather than a broad sector event, as the selloff diverged from the broader healthcare and managed-care complex. The shares traded well below key short-term moving averages, reflecting a technical breakdown as the market absorbed the lowered outlook.
What Comes Next for ALHC
Looking ahead, investors will focus on the company's execution during the Annual Enrollment Period and the initial read on 2027 membership when management provides updates in January. Alignment reiterated a 2027 top-line growth target of at least 20% and said early enrollment results are off to a strong start, but the path back to margin expansion remains a central question. Key risks include continued medical-cost pressure, the intensity of competition in Medicare Advantage, and the outcome of efforts to remediate the California Star Rating shortfall. Analysts will be watching for evidence that claims trends stabilized into September and October as management suggested, and whether corrective initiatives begin to show up in future results.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Explore the page to see which strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALHC's RSI Oscillator climbs out of oversold territory
The RSI Indicator for ALHC moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 54 cases where ALHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on October 02, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 249 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALHC as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ALHC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (6.306) is slightly higher than the industry average of (3.425). P/E Ratio (40.300) is within average values for comparable stocks, (120.437). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement